Srpski arhiv za celokupno lekarstvo 2024 Volume 152, Issue 3-4, Pages: 209-213
https://doi.org/10.2298/SARH231114015L
Full text (
726 KB)
The importance of re-biopsy in the era of molecular therapy for lung cancer
Lalić Nensi 
(University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia), nensi.lalic@mf.uns.ac.rs
Bursać Daliborka (University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia)
Bojović Marko (University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Sremska Kamenica, Serbia)
Nemet Marko (University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia)
Ergelašev Ivan (University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia)
Introduction. Recent epidemiological data highlight that lung cancer incidence and mortality rates remain alarmingly high globally for both men and women. Over the last 10 years, the evolution in treatment corresponds to identifying specific driver mutations within lung tumors and developing inhibitors targeting these mutations. Case outline. A 73-year-old woman was diagnosed with lung adenocarcinoma staged as T4N2M1b at the Institute for Pulmonary Diseases of Vojvodina in February 2019. The Oncology Board recommended molecular analysis of the tumor and palliative radiation therapy for spinal metastases. Molecular testing identified an exon 19 deletion in the epidermal growth factor receptor (EGFR) gene. Following radiation treatment of the spine metastases, the patient began treatment with afatinib in May 2019. After 35 cycles of the aforementioned therapy, in April 2022, a computed tomography scan of the thorax and abdomen showed that the disease had progressed. Despite three liquid biopsies failing to detect the T790M mutation, a subsequent bronchoscopy and tissue re-biopsy confirmed its presence, prompting the initiation of osimertinib treatment. Twelve months into osimertinib therapy, the patient continues to be monitored. Conclusion. EGFR is a crucial predictive biomarker for non-small cell lung cancer. The introduction of specific tyrosine kinase inhibitors – first-generation agents like gefitinib and erlotinib, second-generation afatinib, and introduction of third-generation (osimertinib or lolatinib) when initial treatments are met with resistance, has led to significant therapeutic breakthroughs.
Keywords: lung adenocarcinoma, liquid biopsy, T790M, tissue biopsy
Show references
Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of American pathologists/ international association for the. J Clin Oncol. 2018;36(9):911-9. [DOI: 10.1200/JCO.2017.76.7293] [PMID: 29401004]
Passiglia F, Scagliotti GV. The evolving paradigm of precision medicine in lung cancer. Curr Opin Pulm Med. 2021;27(4):249-54. [DOI: 10.1097/MCP.0000000000000778] [PMID: 33927132]
Jurišić V, Obradovic J, Pavlović S, Djordjevic N. Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol (Amst). 2018;2018:6192187. [DOI: 10.1155/2018/6192187] [PMID: 30406002]
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016(5):CD010383. [DOI: 10.1002/14651858.CD010383.pub2] [PMID: 27223332]
Holleman MS, van Tinteren H, Groen HJM, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: A network meta-analysis. Onco Targets Ther. 2019;12:1413-21. [DOI: 10.2147/OTT.S189438] [PMID: 30863108]
Wu SG, Shih JY. Management of acquired resistance to EGFR TKItargeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. [DOI: 10.1186/s12943-018-0777-1] [PMID: 29455650]
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629- 40. [DOI: 10.1056/NEJMoa1612674] [PMID: 27959700]
Mondoni M, Rinaldo RF, Carlucci P, Terraneo S, Saderi L, Centanni S, et al. Bronchoscopic sampling techniques in the era of technological bronchoscopy. Pulmonology. 2022;28(6):461-71. [DOI: 10.1016/j.pulmoe.2020.06.007] [PMID: 32624385]
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. [DOI: 10.3322/caac.21763] [PMID: 36633525]
Winfree KB, Molife C, Peterson PM, Chen Y, Visseren-Grul CM, Leusch MS, et al. Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations. Future Oncol. 2021;17(22):2867- 81. [DOI: 10.2217/fon-2021-0218] [PMID: 33866796]
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129-59. [DOI: 10.1016/j.jmoldx.2017.11.004] [PMID: 29398453]
Bauml JM, Viteri S, Minchom A, Bazhenova L, Ou S, Schaffer M, et al. FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets. J Thorac Oncol. 2021;16(3):S208-9. [DOI: 10.1016/j.jtho.2021.01.112]
Paz-Ares L, Tan EH, O’Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270-7. [DOI: 10.1093/annonc/mdw611] [PMID: 28426106]
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and secondgeneration EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10-i19. [DOI: 10.1093/annonc/mdx703] [PMID: 29462254]
Passaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377- 91. [DOI: 10.1038/s43018-021-00195-8] [PMID: 35122001]
Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643-52. [DOI: 10.1016/S1470-2045(16)30508-3] [PMID: 27751847]
Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, et al. Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer. Cancer Res Treat. 2023;55(1):112-22. [DOI: 10.4143/crt.2022.381] [PMID: 36049499]
Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC. Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. Yonsei Med J. 2019;60(6):525-34. [DOI: 10.3349/ymj.2019.60.6.525] [PMID: 31124335]